Home > Insider Trading > Filing (0001609351-16-000073)

Filing Details

Accession Number:: 0001609351-16-000073
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-19 16:23:11
Reporting Period:: 2016-07-15

Filing Date:: 2016-07-19
Accepted Time:: 2016-07-19 16:23:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609351	Spark Therapeutics Inc.	ONCE	Biological Products, (No Disgnostic Substances) (2836)	462654405

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610381	Rogerio Coelho Vivaldi	C/O Spark Therapeutics, Inc. 3737 Market Street, Suite 1300 Philadelphia PA 19104	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-07-15	1,000	$3.45	19,716	No	4	M	Direct
Common Stock	Acquisiton	2016-07-15	1,000	$3.45	20,716	No	4	M	Direct
Common Stock	Acquisiton	2016-07-15	5,000	$7.50	25,716	No	4	M	Direct
Common Stock	Disposition	2016-07-15	5,600	$52.96	20,116	No	4	S	Direct
Common Stock	Disposition	2016-07-15	1,400	$53.32	18,716	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2016-07-15	1,000	$0.00	1,000	$3.45
Common Stock	Stock Option (right to buy)	Disposition	2016-07-15	1,000	$0.00	1,000	$3.45
Common Stock	Stock Option (right to buy)	Disposition	2016-07-15	5,000	$0.00	5,000	$7.50

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,116	2024-06-10	No	4	M	Direct
10,203	2024-08-11	No	4	M	Direct
155,186	2024-12-01	No	4	M	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.25 to $53.24, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.25 to $53.50, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
This option was granted on June 10, 2014 and vests over four years, with 25% of the shares underlying the option vesting on April 1, 2015 and the remainder vesting quarterly thereafter.
This option was granted on August 11, 2014 and vests over four years with 25% of the shares underlying the option vesting on May 24, 2015 and the remainder vesting quarterly thereafter.
This option was granted on December 1, 2014 and vests over four years, with 25% of the shares underlying the option vesting on April 1, 2015 and the remainder vesting quarterly thereafter.